Supplementation with lupeol (0.67 gÁkg À1 ) of the AIN-93M-based diet fed for 7 weeks to stroke-prone spontaneously hypertensive rats caused significantly decreased blood pressure as compared with a control group. Urinary 8-hydroxy-2 0 -deoxyguanosine was significantly lower in the lupeol group. Finally, lupeol suppressed the hepatic mRNA expression levels of the genes involved in triglyceride and cholesterol synthesis.
Lupeol has been studied intensively. It is widely distributed in vegetables, fruits, and medicinal plants. 1) Physiological activities of lupeol have been reported in studies, including amelioration of the renal injury associated with hypercholesterolemia and effective combating of oxidative stress-induced cellular injury in Swiss albino mice. 2, 3) Our previous studies indicate that lupeol administration reduced serum triglyceride and cholesterol levels in mice fed a high-fat diet and in human hepatoma cells. 4, 5) Intravenous and oral administration of lupeol reduced blood pressure (BP) in Sprague-Dawley rats. 6) Still, there has been no report on a lupeol effect on BP and lipid metabolism in strokeprone spontaneously hypertensive rats (SHRSP), an animal model of hypertension-related disorders that is similar to human essential hypertension, dyslipidemia, and insulin resistance. 7, 8) Here we report an effect of lupeol administration in BP-lowering activity and the hepatic mRNA expression levels involved in triglyceride and cholesterol synthesis in SHRSP.
Lupeol was prepared as described in our previous report. 5) Male SHRSP/Izumo strain (Japan SLC, Shizuoka, Japan) were housed individually in stainless steel cages under a controlled atmosphere (temperature 23 AE 2 C; humidity 50 AE 10%; 12 h light-dark cycle). After a 1-week acclimatization period, we divided 7-week old SHRSP into two groups and fed them an AIN-93M-based diet for 7 weeks. Lupeol was added at 0.67 gÁkg À1 to the AIN-93M diet in the lupeol group, and not to the control group. The dosage of lupeol used in this study was based on our previous study.
4 ) The rats had free access to these diets and drinking water, and food intake was recorded every day. Every week, systolic BP was measured by the tail cuff method using a BP meter without warming (MK-2000; Muromachi Kikai, Tokyo), as described previously. 9) At the end of the experiment, the rats were anesthetized with diethylether after 16 h of fasting and then sacrificed. Blood was collected from the abdominal aorta, and plasma was separated by centrifugation and stored at À20 C until analysis. The plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities and the levels of triglyceride, total cholesterol, HDL-cholesterol, blood urea nitrogen, and creatinine were measured by colorimetric enzymatic methods (Wako Pure Chemical Co., Osaka, Japan). LDL-cholesterol levels were calculated by the Friedewald formula.
10) Urinary 8-hydroxy-2 0 -deoxyguanosine (8-OHdG) levels were measured by ELISA (Japan Institute for the Control of Aging, Shizuoka, Japan), as described previously. 9) Total RNA was isolated from liver samples using Isogen, a guanidine isothiocyanate-based reagent (Nippon Gene, Tokyo). Five mg of total RNA was used as template to synthesize cDNA, as described previously.
11) Aliquots of the cDNA product were used as the template for quantitative reverse-transcriptase mediated polymerase chain reaction analysis, which was done using an Applied Biosystems 7300 Real Time PCR System (Foster City, CA) and SYBR Premix Ex Taq (Takara Bio Inc., Shiga, Japan). Relative gene expression levels were normalized to the amount of eukaryotic elongation factor-11 (EF-1) mRNA.
11) The primer sequences were as follows: EF-1, 5 0 -GATGGCCCCAAATTCTT-GAAG-3 0 (forward) and 5 0 -GGACCATGTCAACAA-TTGCAG-3 0 (reverse); 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr), 5 0 -AATTGTGTGTGGCACTGTG-ATG-3 0 (forward) and 5 0 -GATCTGTTGTGAACCAT-GTGACTTCT-3 0 (reverse); fatty acid synthase (Fasn), * These authors contributed equally to this work. There were no differences in final body weights and daily food intake among the groups during the experimental period (Table 1) . Lupeol intake did not affect plasma ALT and AST activities (Table 1 ). These findings suggest that lupeol does not induce liver damage under the present experiment conditions. More BP-lowering activity was observed in the lupeol group than in the control group from fifth week to the end of experimental feeding, even though heart rates were not different between the groups ( Table 2 ). The effects were greater than in a previous study, 6 ) probably because we used SHRSP. This is the first report that lupeol has the potential to improve high BP in a model of genetic hypertension. We found that lupeol supplementation significantly lowered urinary 8-OHdG levels as compared with the control diet (p < 0:05), as shown Table 1 , but there was no difference in the plasma levels as to kidney function. It has been reported that higher oxidative stress is associated with hypertension in SHRSP.
12) Furthermore, urinary 8-OHdG has been used as a biomarker of both oxidative DNA damage and oxidative stress. This indicates that decreases in urinary 8-OHdG level due to lupeol administration have an improving effect on oxidative status associated with hypertension in SHRSP.
The mechanism that underlies the lipid improvement effect of lupeol supplementation in SHRSP remains unknown. In this study, the lipid levels in the plasma (triglyceride and total cholesterol) and the liver (total lipids, triglycerides, and total cholesterol) were lower than in the control group, although the difference was not significant. Furthermore, plasma LDL-cholesterol was significantly lower as compared with the control group (Table 1) . We measured the hepatic mRNA expression levels of the markers involved in triglyceride and cholesterol synthesis in order to understand the detailed effects at the molecular level after lupeol administration (Fig. 1) . We found that the mRNA expression levels of Hmgcr, Acaca, and Srebp2 were significantly downregulated in the lupeol group as compared to the control group. Another group has reported that lupeol and lupeol linoleate have beneficial effects in reducing lipid abnormalities in high cholesterol fed rats.
13) The downregulation of the mRNA level of Hmgcr caused by inhibiting the action of lupeol can affect decreases in plasma lipid parameters and fatty acid synthesis in the liver. This is consistent with our previous studies which indicate that lupeol normalizes lipid profiles in a high-fat diet animal model and in hepatocytes. 4, 5) Our data suggest that lupeol decreases the mRNA expression levels of the hepatic genes involved in triglyceride and cholesterol synthesis and may improve lipid metabolism in SHRSP. In addition, the lipid improvement effect of lupeol was independent of its BP-lowering activity.
